Mineralocorticoid Receptor Antagonists in Type 2 Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 140 participants.

Also called NCT02809963

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 140 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02809963
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Denmark (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02809963. Randomized; double masking; primary purpose treatment. Start 2015-11 (registry gives no type); primary completion 2017-11 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Mineralocorticoid Receptor Antagonists in Type 2 Diabetes
Condition
Diabetes Type 2
Intervention (Drug)
Eplerenone
Intervention (Drug)
Placebo
Lead sponsor
Herlev Hospital (class: other)

Record details

Record id
cardio:ct-nct02809963
Content hash
3bdb1c7246a601468913d95d21e969c8577ccba07d9883451c1580ab4bcb4b70